Free Trial
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free CTXR Stock Alerts

Citius Pharmaceuticals (CTXR) Short Interest Ratio & Short Volume

Citius Pharmaceuticals logo
$0.56 -0.03 (-5.00%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$0.57 +0.01 (+2.50%)
As of 06/5/2026 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Citius Pharmaceuticals Short Interest Overview

As of May 15, 2026, Citius Pharmaceuticals (CTXR) had a short interest of 5.16 million shares sold short, representing 19.80% of the public float. This marks a -1.90% decrease in short interest since the prior report. The short interest ratio (days to cover) is 6.8, meaning it would take 6.8 days of the average trading volume of 717,179 shares to cover all short positions.

Current Short Interest
5,163,523 shares
Previous Short Interest
5,263,532 shares
Change Vs. Previous Month
-1.90%
Dollar Volume Sold Short
$3.62 million
Short Interest Ratio
6.8 Days to Cover
Last Record Date
May 15, 2026
Outstanding Shares
27,450,000 shares
Short Percent of Float
19.80%
Today's Trading Volume
259,750 shares
Average Trading Volume
717,179 shares
Today's Volume Vs. Average
36%
Short Selling Citius Pharmaceuticals?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Citius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CTXR Short Interest Over Time

CTXR Days to Cover Over Time

CTXR Percentage of Float Shorted Over Time

Citius Pharmaceuticals Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/20265,163,523 shares $3.62 million -1.9%19.8%6.82 $0.70
4/30/20265,263,532 shares $3.66 million +31.4%24.8%4.28 $0.70
4/15/20264,004,574 shares $3.44 million +2.5%18.8%13.69 $0.86
3/31/20263,905,194 shares $3.51 million -3.5%18.4%6.86 $0.90
3/13/20264,044,938 shares $3.89 million +21.0%19.0%3.61 $0.96
2/27/20263,341,948 shares $2.47 million +6.8%15.7%11.6 $0.74
2/13/20263,128,019 shares $2.39 million +15.0%15.7%4.39 $0.77
1/30/20262,719,644 shares $2.01 million -6.9%14.7%9.91 $0.74
1/15/20262,922,542 shares $2.50 million -7.7%15.8%9.96 $0.86
12/31/20253,166,818 shares $2.46 million +20.5%17.1%1.24 $0.78
12/15/20252,628,101 shares $2.79 million +9.6%17.3%7.1 $1.06
11/28/20252,398,448 shares $3.42 million +2.5%15.8%3.15 $1.43
11/14/20252,339,794 shares $2.29 million -9.3%15.4%5.59 $0.98
10/31/20252,580,788 shares $4.08 million +63.1%17.0%1.19 $1.58
10/15/20251,580,000 shares $2.20 million +61.4%9.1%2.2 $1.39
9/30/2025978,800 shares $1.21 million -5.0%6.1%2 $1.24
9/15/20251,030,000 shares $1.17 million +29.5%6.4%1.2 $1.14
8/31/2025795,300 shares $1.06 million +20.8%5.0%0.3 $1.33
8/15/2025658,600 shares $875.94 thousand -14.4%4.1%0.3 $1.33
7/31/2025769,300 shares $1.05 million -31.3%7.3%0.3 $1.37
7/15/20251,120,000 shares $1.83 million +15.5%10.6%0.4 $1.63
6/30/2025969,700 shares $1.54 million -28.2%9.2%0.4 $1.59
6/15/20251,350,000 shares $1.18 million +103.1%12.8%0.6 $0.87
5/31/2025664,600 shares $459.50 thousand +10.1%6.9%0.3 $0.69
5/15/2025603,400 shares $499.55 thousand -10.0%6.2%2.1 $0.83
4/30/2025670,600 shares $513.01 thousand -11.3%7.2%2.2 $0.77
4/15/2025755,900 shares $755.90 thousand +11.0%8.6%2.6 $1.00
3/31/2025681,200 shares $1.01 million +31.6%7.7%2.3 $1.49
3/15/2025517,600 shares $776.40 thousand -5.4%6.4%3.7 $1.50
2/28/2025547,000 shares $902.55 thousand +1.3%6.8%3.6 $1.65
2/15/2025540,100 shares $1.45 million +5.1%6.7%1.8 $2.69
1/31/2025513,900 shares $1.38 million -12.5%6.4%1.8 $2.69
1/15/2025587,000 shares $2.00 million -1.4%7.3%2.2 $3.40
12/31/2024595,300 shares $2.38 million +13.6%7.5%2.3 $4.00
12/15/2024523,900 shares $1.46 million -13.2%7.3%2.3 $2.79
11/30/2024603,700 shares $2.00 million +12.2%8.4%2.8 $3.32
11/15/2024537,900 shares $2.69 million -95.4%7.5%2.8 $5.00
10/31/202411,790,000 shares $4.39 million -5.1%N/A10.5 $0.37
10/15/202412,420,000 shares $4.65 million -2.7%N/A8.9 $0.37
9/30/202412,770,000 shares $6.39 million +1.9%N/A7.2 $0.50
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad)

Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel

See how to get positioned in SpaceX before the announcement goes public
9/15/202412,530,000 shares $6.51 million -6.4%N/A5.8 $0.52
8/31/202413,390,000 shares $7.63 million +9.0%N/A6.3 $0.57
8/15/202412,280,000 shares $7.20 million -16.1%N/A5.5 $0.59
7/31/202414,630,000 shares $13.24 million +21.9%N/A5.8 $0.91
7/15/202412,000,000 shares $9.18 million -15.2%N/A5.4 $0.77
6/30/202414,150,000 shares $8.26 million -8.5%N/A7.1 $0.58
6/15/202415,460,000 shares $9.67 million -2.8%N/A9.9 $0.63
5/31/202415,910,000 shares $11.10 million +9.9%N/A10.6 $0.70
5/15/202414,480,000 shares $9.05 million +0.4%N/A10.5 $0.62
4/30/202414,430,000 shares $10.77 million +9.4%N/A15.6 $0.75
4/15/202413,190,000 shares $10.09 million +6.1%N/A15.5 $0.77
3/31/202412,430,000 shares $11.15 million +2.1%N/A16.9 $0.90
3/15/202412,180,000 shares $8.97 million +2.7%N/A18.6 $0.74
2/29/202411,860,000 shares $9.11 million +2.4%N/A18.9 $0.77
2/15/202411,580,000 shares $9.75 million -0.3%N/A18.5 $0.84
1/31/202411,610,000 shares $7.21 million -16.7%N/A20.2 $0.62
1/15/202413,940,000 shares $10.46 million -4.7%N/A23.6 $0.75
12/31/202314,620,000 shares $11.06 million +8.6%N/A26.2 $0.76
12/15/202313,460,000 shares $10.73 million -15.0%N/A25.1 $0.80
11/30/202315,830,000 shares $12.20 million -1.3%N/A25.1 $0.77
11/15/202316,030,000 shares $12.31 million -5.1%N/A25.1 $0.77
10/31/202316,890,000 shares $12.71 million -1.9%N/A23.3 $0.75
10/15/202317,210,000 shares $12.00 million -7.2%N/A17.3 $0.70
9/30/202318,540,000 shares $12.69 million -4.5%N/A18 $0.68
9/15/202319,420,000 shares $14.74 million -1.1%N/A15.9 $0.76
8/31/202319,640,000 shares $17.92 million -1.1%N/A13.3 $0.91
8/15/202319,850,000 shares $17.10 million -4.6%N/A12.7 $0.86
7/31/202320,800,000 shares $20.59 million +2.0%N/A10.8 $0.99
7/15/202320,390,000 shares $24.26 million +8.7%N/A11 $1.19
6/30/202318,760,000 shares $22.51 million +27.9%N/A9.9 $1.20
6/15/202314,670,000 shares $18.48 million +6.6%N/A8.2 $1.26
5/31/202313,760,000 shares $15.96 million +13.4%N/A9.5 $1.16
5/15/202312,130,000 shares $15.53 million -10.8%N/A8.9 $1.28
4/30/202313,600,000 shares $19.72 million +6.7%N/A14.3 $1.45
4/15/202312,750,000 shares $20.91 million +6.5%9.5%14 $1.64
3/31/202311,970,000 shares $14.00 million +4.5%8.9%13.5 $1.17
3/15/202311,450,000 shares $11.79 million +1.5%8.6%13.1 $1.03
2/28/202311,280,000 shares $12.97 million +2.8%8.4%13.6 $1.15
2/15/202310,970,000 shares $13.49 million -5.4%8.2%13.5 $1.23
1/31/202311,600,000 shares $16.12 million +6.6%8.7%14.9 $1.39
1/15/202310,880,000 shares $12.19 million -0.7%8.1%15.3 $1.12
12/30/202210,960,000 shares $8.66 million -3.4%8.2%22 $0.79
12/15/202211,340,000 shares $12.81 million -0.4%N/A23.1 $1.13
11/30/202211,390,000 shares $13.33 million +4.5%N/A23.2 $1.17
11/15/202210,900,000 shares $11.66 million +1.3%N/A22.2 $1.07
10/31/202210,760,000 shares $11.62 million -3.0%N/A19.2 $1.08
10/15/202211,090,000 shares $11.98 million -0.1%N/A19.5 $1.08
9/30/202211,100,000 shares $13.43 million +6.3%N/A17.8 $1.21
9/15/202210,440,000 shares $12.84 million +3.6%N/A12.7 $1.23
8/31/202210,080,000 shares $12.40 million +2.0%N/A11.1 $1.23
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad)

Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel

See how to get positioned in SpaceX before the announcement goes public
8/15/20229,880,000 shares $12.55 million -0.7%N/A9.1 $1.27
7/31/20229,950,000 shares $8.89 million -4.8%N/A7.8 $0.89
7/15/202210,450,000 shares $9.54 million +1.1%N/A6.6 $0.91
6/30/202210,340,000 shares $9.51 million -29.1%N/A5.2 $0.92
6/15/202214,590,000 shares $13.92 million -2.7%N/A7.1 $0.95
5/31/202214,990,000 shares $14.09 million +7.2%11.2%7.9 $0.94
5/15/202213,990,000 shares $12.52 million +5.7%10.5%7.6 $0.90
4/30/202213,230,000 shares $13.36 million +25.1%9.9%7.1 $1.01
4/15/202210,580,000 shares $16.40 million +13.6%7.9%6.3 $1.55
3/31/20229,310,000 shares $16.66 million +2.4%7.0%6.2 $1.79
3/15/20229,090,000 shares $14.36 million +1.8%6.8%6.9 $1.58
2/28/20228,930,000 shares $13.75 million -11.2%6.7%6.2 $1.54
2/15/202210,060,000 shares $16.40 million -6.1%7.5%6.5 $1.63
1/31/202210,710,000 shares $16.17 million -5.3%8.0%6.7 $1.51
1/15/202211,310,000 shares $17.30 million -7.0%8.5%6.7 $1.53
12/31/202112,160,000 shares $18.73 million -7.3%9.1%6.6 $1.54
12/15/202113,110,000 shares $22.29 million +2.5%9.8%6.7 $1.70
11/30/202112,790,000 shares $21.62 million -5.0%9.6%6.2 $1.69
11/15/202113,460,000 shares $24.36 million -7.0%10.1%5.6 $1.81
10/29/202114,470,000 shares $27.06 million +2.1%10.8%5.9 $1.87
10/15/202114,170,000 shares $29.62 million -2.0%10.6%5.3 $2.09
9/30/202114,460,000 shares $29.35 million +0.4%10.8%4.9 $2.03
9/15/202114,410,000 shares $29.25 million +11.2%10.8%2.6 $2.03
8/31/202112,960,000 shares $29.16 million -5.4%9.8%1.6 $2.25
8/13/202113,700,000 shares $24.80 million -6.0%10.3%1.6 $1.81
7/30/202114,570,000 shares $27.54 million -13.9%11.8%1.7 $1.89
7/15/202116,920,000 shares $32.49 million -20.9%13.7%1.7 $1.92
6/30/202121,400,000 shares $74.47 million +40.4%17.4%2.1 $3.48
6/15/202115,240,000 shares $49.23 million -3.7%12.4%2 $3.23

CTXR Short Interest - Frequently Asked Questions

Short interest is the volume of Citius Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 5,163,523 shares of CTXR short. 19.80% of Citius Pharmaceuticals' shares are currently sold short. Learn More on Citius Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTXR shares currently have a short interest ratio of 6.8. Learn More on Citius Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.80% of Citius Pharmaceuticals' floating shares are currently sold short.

Citius Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 5,163,523 shares, a decline of 1.9% from the previous total of 5,263,532 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

19.80% of Citius Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Citius Pharmaceuticals: Seres Therapeutics, Inc. (5.56%), Gain Therapeutics, Inc. (7.73%), BioHarvest Sciences Inc. (0.34%), Pliant Therapeutics, Inc. (6.05%), Acrivon Therapeutics, Inc. (6.62%), XBiotech Inc. (0.87%), Lixte Biotechnology Holdings, Inc. (0.63%), Prima BioMed Ltd (3.60%), Lifevantage Corporation (36.47%), TScan Therapeutics, Inc. (1.43%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($80.71 billion), Invesco QQQ ($47.96 billion), iShares Russell 2000 ETF ($22.13 billion), Western Digital Corporation ($14.35 billion), Sandisk Corporation ($12.86 billion), Salesforce Inc. ($10.89 billion), Nebius Group N.V. ($9.92 billion), SPDR S&P Biotech ETF ($9.72 billion), Lumentum Holdings Inc. ($8.89 billion), and iShares 20+ Year Treasury Bond ETF ($8.18 billion). View all of the most shorted stocks.

Short selling CTXR is an investing strategy that aims to generate trading profit from Citius Pharmaceuticals as its price is falling. CTXR shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Citius Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CTXR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTXR, twice per month. The most recent reporting period available is May, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CTXR:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:CTXR) was last updated on 6/7/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel